4DQSAR
Bluelighter
- Joined
- Feb 3, 2025
- Messages
- 5,436
OK - I have noted a few really odd things about tapentadol.
I've read claims that it's affinity for the MOR is just 1/50th that of morphine and a few sources give the affinity µM, not nM which sort of agrees with that statement.
HOWEVER I'm almost certain I've also read that tapentadol is classed as a 'superagonist' i.e. it only weakly binds to the MOR, but it's activity at the MOR is far higher than classical opioids.
This MAY explain why although not that potent (I note the BNF suggests a minimum dose of 50mg although 250mg SR formulations are available), it appears to produce notable analgesic activity but at the cost of a particularly nasty AWS.
In the UK one consultant has even written a paper specifically on the topic of tapentadol detoxification. I'm assuming that for people who get on with or even enjoy the stimulant activity, that AWS might be significantly different in character.
Forensic journals appear to suggest that somewhat like tramadol, fatal overdoses may not present in the same manner as those produced by 'classical' opioid with seizures being a particular issue. I have no idea of the scale of the problem but the UK government was sufficiently concerned to release a warning:
www.gov.uk
I am prepared to bet that tapentadol, like tramadol, will fall out of favour with British clinicians. Maybe not an outright ban, but I can imagine clinicians deciding that in patients for whom tapentadol is will tolerated, they will continue to prescribe... but I suggest that it will become a second-line treatment in new patients. I was never offered the stuff but then again, I am subject to seizures so presume my doctor discounted tapentadol out of hand.
I've read claims that it's affinity for the MOR is just 1/50th that of morphine and a few sources give the affinity µM, not nM which sort of agrees with that statement.
HOWEVER I'm almost certain I've also read that tapentadol is classed as a 'superagonist' i.e. it only weakly binds to the MOR, but it's activity at the MOR is far higher than classical opioids.
This MAY explain why although not that potent (I note the BNF suggests a minimum dose of 50mg although 250mg SR formulations are available), it appears to produce notable analgesic activity but at the cost of a particularly nasty AWS.
In the UK one consultant has even written a paper specifically on the topic of tapentadol detoxification. I'm assuming that for people who get on with or even enjoy the stimulant activity, that AWS might be significantly different in character.
Forensic journals appear to suggest that somewhat like tramadol, fatal overdoses may not present in the same manner as those produced by 'classical' opioid with seizures being a particular issue. I have no idea of the scale of the problem but the UK government was sufficiently concerned to release a warning:
Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines
Tapentadol may increase seizure risk in patients taking other medicines that lower seizure threshold, for example, antidepressants and antipsychotics. Serotonin syndrome has also been reported when tapentadol is used in combination with serotoninergic antidepressants.
I am prepared to bet that tapentadol, like tramadol, will fall out of favour with British clinicians. Maybe not an outright ban, but I can imagine clinicians deciding that in patients for whom tapentadol is will tolerated, they will continue to prescribe... but I suggest that it will become a second-line treatment in new patients. I was never offered the stuff but then again, I am subject to seizures so presume my doctor discounted tapentadol out of hand.
